Bevacizumab News and Research

RSS

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Pfizer Oncology today announced that important data from its lung cancer and renal cell carcinoma (RCC) portfolios will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Vienna, Austria, September 28 - October 2, 2012.

18 Sep 2012

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

12 Aug 2012

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Breast cancer is the most important cancer for women in the developed world. About 20% of all patients diagnosed with breast cancer die of metastatic disease.

1 Aug 2012

Nottingham researchers to lead Avastin clinical study for AMD

Nottingham researchers are leading a study to test the effectiveness of a controversial drug in the treatment of a common loss of vision.

12 Jul 2012

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.

11 Jul 2012

Ampio announces results from Optina trial on DME

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), announced the significant results from their further analysis of its Optina trial on DME.

9 Jul 2012

Cancer Therapeutics announces validation and performance of CTx-294886 plus Avastin

5 Jul 2012

Cancer Therapeutics reveals proof of concept for second development drug

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.

4 Jul 2012

Liver metastases predicts shorter overall survival in men with mCRPC

Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago.

2 Jun 2012

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.

31 May 2012

GE to provide attendees with overview of new oncology solutions at ASCO annual meeting

GE Healthcare, is working to help physicians potentially improve patient care throughout the breast cancer journey through one of the most comprehensive portfolios of technologies in the industry available today.

31 May 2012

AngioPredict project to focus on patients with metastatic colorectal cancer

The Royal College of Surgeons in Ireland (RCSI) is leading an international team of scientists on a major research study which aims to predict colorectal cancer patients' response to the 'angiogenesis inhibitor' class of anti-cancer drug which prevents growth of tumour blood vessels. The study will facilitate a more focused therapeutic approach thus limiting side-effects in patients.

28 May 2012

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents.

23 May 2012

Biomarker neutralizes effect of bevacizumab in pancreas and kidney cancer patients

Diether Lambrechts (VIB - KU Leuven) said "in two large clinical studies with patients with advanced stages of pancreas and kidney cancer a variant in the DNA was discovered that identified patients who did not respond well to the prescribed course of bevacizumab.

21 May 2012

Cheaper anti-blindness drug could save NHS £85 million annually

Avastin (bevacizumab), which is used to treat wet age-related macular degeneration – the most common cause of blindness among the elderly costs only £60 per injection. But despite trials showing it is no less effective, another drug, Lucentis, is the current official choice, even though it costs £700 per shot. Avastin is intended to treat bowel cancer, but research by the National Institute for Health Research has shown that it also works just as effectively and safely as Lucentis in treating Wet AMD.

8 May 2012

NCIC CTG, Oncolytics to conduct REOLYSIN Phase II study in colorectal cancer

Oncolytics Biotech Inc. announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer.

4 May 2012

Bevacizumab equivalent to ranibizumab in treating wet AMD

In a landmark drug-comparison study, Cleveland Clinic researchers found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet age-related macular degeneration (AMD) through two years.

2 May 2012

VeriStrat test may be useful for NSCLC clinical decision-making

Results from the combined analysis of two European Phase II trials were presented today at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy bevacizumab plus erlotinib.

21 Apr 2012